Royal Bank Of Canada Codiak Bio Sciences, Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.82 - $3.19 $121 - $472	148 New	148 $0
Q2 2022 Aug 15, 2022	SELL	$2.24 - $6.96 $2,190 - $6,806	-978 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.3 - $12.95 $11,201 - $33,734	-2,605 Reduced 72.7%	978 $6,000
Q4 2021 Feb 14, 2022	BUY	$10.0 - $16.78 $20,530 - $34,449	2,053 Added 134.18%	3,583 $40,000
Q3 2021 Nov 15, 2021	BUY	$15.58 - $22.88 $7,088 - $10,410	455 Added 42.33%	1,530 $25,000
Q2 2021 Aug 16, 2021	BUY	$11.72 - $26.81 $12,599 - $28,820	1,075 New	1,075 $20,000

238K

Ticker CDAK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,995,200
Market Cap $360K
Description
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.